Nkarta Inc is a biotechnology company focused on the development of novel cell therapies to treat cancer
The company specializes in engineering natural killer (NK) cells, which are a type of immune cell known for their ability to recognize and destroy tumors. Nkarta aims to harness the power of these cells to create innovative, targeted therapies that can enhance the body's immune response against various forms of cancer. Through its research and clinical development efforts, Nkarta seeks to provide meaningful treatment options for patients facing challenging malignancies.
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01.
Shares of Cutera, Inc. (NASDAQCUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
Stocks slightly retreated during New York’s morning session on Friday, following another robust week of gains fueled by a dovish Federal Reserve meeting, which underscored Chair Jerome Powell‘s readiness to initiate interest
Nkarta closed patient enrollment in NKX101 clinical trial, reallocating focus to lead program NKX019 for autoimmune disease. Recent expansion into autoimmune disease with FDA clearance for NKX019 in lupus nephritis signals company growth. Financially sound with $250.9 million in cash, expected to sustain operations through 2026.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
